Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp to be presented during oral abstract.
The anti-TIM3 monoclonal antibody, cobolimab utilized in combination with the anti-PD–1 antibody dostarlimab-gxly demonstrated promising signs of clinical activity and an acceptable safety profile across all dose levels in heavily pretreated patients with advanced/metastatic non–small cell lung cancer.
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab , in patients with microsatellite stable . -Today at 07:31 am- MarketScreener
Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.